12/17/2020

IVI-SK’s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

Primary analysis also confirms safety of Vi-DT   December 17, 2020 – SEOUL, South Korea – Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary […]
12/19/2020

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

12/31/2020

2020 Year in Review

01/05/2021

Cellid, IVI exchange ‘COVID-19 Vaccine Research Service Contract’

IVI to analyze samples from Phase 1/2a trials of Cellid’s COVID-19 vaccine to evaluate immunogenicity   January 5, 2021, SEOUL, Korea –  Cellid and the International Vaccine Institute (IVI) have exchanged a collaborative research agreement to analyze the immunogenicity of the COVID-19 vaccine “AdCLD-CoV19”.   […]